Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Thor Medical ASA is a Norway-based biopharmaceutical company specializing in the production and supply of alpha-particle emitters for advanced cancer therapy. It extracts radioactive decay products from naturally occurring thorium-232 (Th-232), generating key isotopes such as Lead-212 (Pb-212), Radium-224 (Ra-224), and Thorium-228 (Th-228) without requiring nuclear reactors or accelerators. This proprietary technology enables high-efficiency manufacturing that is cost-competitive and environmentally friendly, with reprocessed chemicals and minimal waste, ensuring a reliable, continuous supply due to thorium's long half-life of 14 billion years. The alpha particles deliver high energy over a short range, precisely targeting and eradicating cancer cells while sparing surrounding healthy tissue, supporting radioligand therapy (RLT) and radionuclide therapy (RNT) for cancers with high unmet needs. Headquartered in Oslo with about 9 employees, Thor Medical ASA operates in the biotechnology sector, recently securing strategic supply agreements with partners like Oncoinvent and AdvanCell to fuel growth in innovative oncology treatments. Founded in 2017 from thorium research initiatives, it plays a pivotal role in enabling next-generation targeted radiopharmaceuticals.